CD30 and ALK combination therapy has high therapeutic potency in RANBP2-ALK-rearranged epithelioid inflammatory myofibroblastic sarcoma

BACKGROUND: Epithelioid inflammatory myofibroblastic sarcoma (eIMS) is characterised by perinuclear ALK localisation, CD30 expression and early relapse despite crizotinib treatment. We aimed to identify therapies to prevent and/or treat ALK inhibitor resistance. METHODS: Malignant ascites, from an e...

Descripción completa

Detalles Bibliográficos
Autores principales: Fordham, Ashleigh M., Xie, Jinhan, Gifford, Andrew J., Wadham, Carol, Morgan, Lisa T., Mould, Emily V. A., Fadia, Mitali, Zhai, Lei, Massudi, Hassina, Ali, Zara S., Marshall, Glenn M., Lukeis, Robyn E., Fletcher, Jamie I., MacKenzie, Karen L., Trahair, Toby N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7524717/
https://www.ncbi.nlm.nih.gov/pubmed/32684628
http://dx.doi.org/10.1038/s41416-020-0996-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7524717/
https://www.ncbi.nlm.nih.gov/pubmed/32684628
http://dx.doi.org/10.1038/s41416-020-0996-2

Ejemplares similares